Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Sodium Carbonate | HCID 10340 | — |
| Reactant | HCID 20516774 | HCID 20516774 | — |
| Reactant | HCID 20516775 | HCID 20516775 | — |
| Reactant | HCID 20516784 | HCID 20516784 | — |
| Solvent | 1,2-Dichloroethane | HCID 11 | — |
| Solvent | Methylamine | HCID 6329 | — |
| Solvent | Acetonitrile | HCID 6342 | — |
| Product | HCID 20516776 | HCID 20516776 | — |
Reaction Steps
A 1,2-dichloroethane solution of [6,8-dichloro-5-(o-fluorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-7-yl]isocyanate, prepared in analogy to the procedure described in paragraph (a) of Example 4 from 5 g (14.2 mmol) of 7-amino-6,8-dichloro-5-(o-fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one, is treated with a suspension of 6 g of sodium carbonate in 34 ml of acetonitrile and 2 ml of methylamine. The mixture is stirred at room temperature for 66 hours, concentrated in vacuo and the residue is taken up in 1.5 liter of methylene chloride/ethanol (4:1). The organic phase is washed with saturated sodium chloride solution, dried and evaporated. The residue is chromatographed on 300 g of silica gel using methylene chloride/ethyl acetate (4:1) for the elution, there being obtained 1-[6,8-dichloro-5-(o-fluorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-7-yl]-3-methylurea. After recrystallisation from ether, the product melts at 213°-214° C.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US04361511 |
|---|
| Source dataset | uspto-grants-1982_11 |
|---|
| ORD ID | ord-f8dacd9724c743568a21aa2859ee7cd5 |
|---|
| Source note | uspto-grants-1982_11 |
|---|